Established 1999
 
8,000 companies from
USA,Canada and India.
 
   
Search over 25,000 News & Earnings Archives    
 
Earnings Analysis: 
Jones Soda Profit More than Triples
Author: 123jump.com Staff
123jump.com
Last Update: 12:44 PM EST March 09 2007



Email article | Print article

Lumera widens its fourth-quarter losses on higher revenue. AeroVironment third-quarter earnings almost doubled, mainly due to strong demand for its unmanned aircraft. NovAtel fourth-quarter profit was relatively flat, as an increase in revenue was offset by higher costs. Jones Soda fourth-quarter profit more than tripled on strong sales and improved gross margins. Encysive Pharmaceuticals fourth-quarter loss widened as it spent money to launch its hypertension drug candidate Thelin.

 
Lumera Corp. (LMRA: chart), which makes polymer-based devices for the bioscience and electro-optics industries, widened its fourth-quarter losses to $3.13 million, or 17 cents per share, compared with $2.62 million, or 16 cents per share, in the year-ago period. Revenue climbed to $1.16 million versus $240,000 in the same period a year earlier.

AeroVironment Inc. (AVAV: chart), maker of unmanned aircraft systems, said that its third-quarter net profit increased to $8.89 million, or 57 cents per share, compared with $4.39 million, or 29 cents per share, in the year-ago period. Revenue climbed to $46.3 million against $35.5 million in the same period a year earlier.

NovAtel Inc. (NGPS: chart), maker of global positioning system receivers and components, reported fourth-quarter net income of C$5.14 million ($4.6 million) or 58 Canadian cents a share (52 cents), compared with C$5.13 million, or 58 Canadian cents a share, in the year-ago period. Revenues climbed to C$19.2 million versus C$16.2 million in the same period a year earlier.

Jones Soda Co. (JSDA: chart), natural soda maker, said that its fourth-quarter net earnings increased to $2.06 million, or 8 cents per share, compared with $580,245, or 3 cents per share, in the year-ago period. Revenue climbed to $10.05 million against $8.75 million in the same period a year ago.

Encysive Pharmaceuticals (ENCY: chart), drug developer, said fourth-quarter losses widened to $25.8 million, 44 cents a share, compared with $19.4 million, or 33 cents per share, a year earlier, due primarily to costs related to the launch of Thelin tablets in Europe and maintaining its commercial infrastructure in the U.S. Revenue declined to $5.4 million versus $5.6 million in the same period a year ago.
More: Earnings Archive

 



350 Fund Managers Interviews - 10-year Annual earnings on 4,600 U.S. companies - 20-quarter Earnings on 3,800 U.S. companies - 3,200 U.S. IPO Prospectuses
- 2,100 Economic data releases from U.S., EU, UK, India, HK and Australia. 10-year Annual reports on 3,500 U.S. companies -
U.S. Earnings Calendar with 4,800 companies - 90,000 10-K reports - 26,000 Global markets news archive - 2,200 Earnings Conference Call Summaries

© 1999-2008 123jump.com. All rights reserved